

21 November 2017 EMA/HMPC/329755/2017 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Curcuma longa* L. (*C. domestica* Valeton), rhizoma

Draft

Initial assessment	
Discussion in Working Party on European Union monographs and	September 2008
European Union list (MLWP)	November 2008
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	6 November 2008
End of consultation (deadline for comments). Comments should be	
provided using this <u>template</u> to <u>hmpc.secretariat@ema.europa.eu</u> >	15 March 2009
Re-discussion in MLWP	July 2009
	September 2009
	November 2009
Adoption by HMPC	12 November 2009
First revision	
Discussion in Working Party on European Union monographs and list	Mar 2017
(MLWP)	May 2017
	Jul 2017
	Sep 2017
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	21 November 2017
Start pf the public consultation	15 December 2017
End of consultation (deadline for comments). Comments should be provided using this <u>template</u> to <u>hmpc.secretariat@ema.europa.eu</u>	15 March 2018

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs;
	traditional use; Curcuma longa L.; Curcuma longae rhizoma; turmeric root



BG (bulgarski): Куркума, коренище CS (čeština): kořen kurkumy dlouhé

DA (dansk): Gurkemeje

DE (Deutsch): Curcumawurzelstock EL (elliniká): κουρκούμης μακράς ρίζωμα

EN (English): turmeric

ES (español): cúrcuma longa, rizoma de

ET (eesti keel): kollajuure juurikas FI (suomi): maustekurkuma, maavarsi FR (français): curcuma long (rhizome de)

HR (hrvatski): kurkumin podanak

HU (magyar): indiai kurkuma gyökértörzs

IT (italiano): Curcuma rizoma

LT (lietuvių kalba): Dažinių ciberžolių

šakniastiebiai

LV (latviešu valoda): Garās kurkumas saknenis

MT (Malti): riżoma tat-turmerik NL (Nederlands): geelwortel PL (polski): Kłącze kurkumy

PT (português): curcuma

RO (română): rizom de turmeric

SK (slovenčina): podzemok kurkumy pravej

SL (slovenščina): korenika kurkume SV (svenska): gurkmeja, jordstam

IS (íslenska):

NO (norsk): gurkemeierot

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma

EMA/HMPC/329755/2017 Page 2/7

European Union herbal monograph on *Curcuma longa* L., rhizoma

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC Curcuma longa L., rhizoma (turmeric root)
	i) Herbal substance
	Not applicable
	ii) Herbal preparations
	a) Powdered herbal substance
	b) Comminuted herbal substance
	c) Tincture (ratio of herbal substance to extraction solvent 1:10), extraction solvent ethanol 70% (V/V)
	d) Dry extract (DER 13-25:1), extraction solvent ethanol 96% (V/V)
	e) Dry extract (DER 5.5-6.5:1), extraction solvent ethanol 50% (V/V)
	f) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 70% (V/V)

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use.
	Herbal preparations in liquid or solid dosage forms for oral use.

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality quidance.

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma ${\rm EMA/HMPC/329755/2017}$

The material complies with the Ph. Eur. monograph (ref. 2543).

Well-established use	Traditional use
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product used for the relief of digestive disturbances, such as feelings of fullness, slow digestion and flatulence. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration³

Well-established use	Traditional use
	Posology
	Adults and Elderly Daily dose
	a) Powdered herbal substance: 1.5-3.0 g daily;
	d) Dry extract (13-25:1): 90-162 mg, divided in 2-5 partial doses daily;
	Single dose
	b) Herbal tea: 0.5-1.0 g comminuted herbal substance in 150 ml of boiling water as an infusion, 2-3 times daily;
	c) Tincture (1:10): 0.5-1 ml, 3 times daily;
	e) Dry extract (5.5-6.5:1): 100-200 mg, 2 times daily;
	f) Tincture (1:5): 10 ml once daily or 5 ml in 60 ml water, 3 times daily;
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 `Special warnings and precautions for use').

³ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

rhizoma EMA/HMPC/329755/2017 Page 4/7

Well-established use	Traditional use
	Duration of use
	If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.
	Due to possible stimulation on bile secretion Curcuma longa is not recommended in case of obstruction of the bile duct, cholangitis, liver disease, gallstones and any other biliary diseases.
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	For tinctures containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported

Page 5/7

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
	No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Mild symptoms of dry mouth, flatulence and gastric irritation may occur. The frequency is not known.
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of

Page 6/7

Well-established use	Traditional use
	Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity,
	genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable

7. Date of compilation/last revision

21 November 2017